BACTERIAL ENDOTOXINS AND OTHER MATERIALS OF MICROBIAL ORIGINHAVE BEEN PREPARED IN NONTOXIC AND NONALLERGENIC FORMS THAT RETAIN THE CAPACITY TO MODIFY, IN A BENEFICIAL FASHION, CERTAIN BIOLOGICAL RESPONSES.

BACTERIAL ENDOTOXINS AND OTHER MATERIALS OF MICROBIAL ORIGINHAVE BEEN PREPARED IN NONTOXIC AND NONALLERGENIC FORMS THAT RETAIN THE CAPACITY TO MODIFY, IN A BENEFICIAL FASHION, CERTAIN BIOLOGICAL RESPONSES. THE ULTIMATE OBJECTIVE OF THESE INVESTIGATIONS IS TO PROVIDE, IN A COST-EFFECTIVE MANNER, STANDARDIZED AND COMMERCIAL PREPARATIONS OF THESE MATERIALS THAT CAN USED FOR IMMUNOTHERAPY OF CANCER. TO THIS END, DURING PHASE I OF THE PROJECT, INITIAL PREPARATIONS OF DETOXIFIED ENDOTOXINS WILL BE SUPPLIED FOR ESTABLISHED ANTITUMOR SCREENS; NEW COMBINATIONS WILL BE PREPARED WITH THESE DETOXIFIED ENDOTOXINS AND OTHER BIO- LOGICAL RESPONSE MODIFIERS; MURINE MODELS OF LYMPHATIC, OVARIAN, SKIN, AND BLADDER CANCERS WILL BE ESTABLISHED FOR TESTING SUSCEPTIBILITY TO IMMUNOTHERAPY; AND FORMULATIONS OFTHE IMMUNOMODULATORS AS ADJUVANTS FOR USE WITH CANCER CELL ANTIGENS WILL BE INVESTIGATED. SUBSEQUENTLY, DURING PHASE II, VARIOUS FORMULATIONS OF THE IMMUNOTHERAPEUTICS WILL BE TESTED IN NCI SCREENS, IN THE INHOUSE TRANSPLANTABLE TUMOR MODELS, AND AS ADJUVANTS FOR VACCINES IN TWO SPONTANEOUS TUMOR SYSTEMS. ANY RESPONSE MODIFIERS THAT DEMONSTRATE POTENTIAL FOR ELICITING A THERAPEUTIC RESPONSE TO CANCERS WILL BECOME CANDIDATES FOR INCLUSION IN AN IND FOR CLINICAL TESTING IN HUMANS.